Richard Kotomori
Psychiatry · Riverside, CANPI 1215059084
Payments from drug & device makers
Across 1,041 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Ironshore Pharmaceuticals Inc.$1K
- plus $8K from 25 others
What the payments were for
- Food & beverage$16,62399%
- Education$1961%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 127 | $2,137 |
| Otsuka America Pharmaceutical, Inc. | 118 | $1,570 |
| Neurocrine Biosciences, Inc. | 63 | $1,356 |
| AbbVie(2 entities) | 90 | $1,282 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 62 | $1,164 |
| Ironshore Pharmaceuticals Inc. | 66 | $1,050 |
| Tris Pharma Inc | 51 | $859 |
| Sunovion Pharmaceuticals Inc. | 65 | $819 |
| Takeda Pharmaceuticals U.S.A., Inc. | 61 | $780 |
| Teva Pharmaceuticals USA, Inc. | 36 | $665 |
| Supernus Pharmaceuticals, Inc. | 55 | $644 |
| Vanda Pharmaceuticals Inc. | 31 | $578 |
| Lundbeck LLC | 35 | $527 |
| Johnson & Johnson | 23 | $512 |
| Almatica Pharma LLC | 22 | $475 |
| Corium, LLC | 24 | $463 |
| Axsome Therapeutics, Inc. | 18 | $337 |
| E.r. Squibb & Sons, L.L.C. | 20 | $291 |
| Collegium Pharmaceutical, Inc. | 17 | $239 |
| Bausch Health US, LLC | 10 | $237 |
| Noven Therapeutics, LLC | 11 | $215 |
| Neos Therapeutics, LP | 9 | $196 |
| Merck | 6 | $120 |
| Idorsia Pharmaceuticals US Inc | 4 | $86 |
| Adlon Therapeutics L.p. | 4 | $68 |
| Biogen | 2 | $35 |
| Vertical Pharmaceuticals, LLC | 2 | $32 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Harmony Biosciences LLC | 1 | $24 |
| Eisai Inc. | 1 | $20 |
| Travere Therapeutics, Inc. | 6 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$117
How this compares
$16,818 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 57 | $78,598 |
| AristadaAripiprazole Lauroxil | 12 | $33,978 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $19,123 |
| VyvanseLisdexamfetamine Dimesylate | 19 | $12,007 |
| TrintellixVortioxetine Hydrobromide | 12 | $7,780 |
| QuviviqDaridorexant Hcl | 16 | $7,687 |
| FetzimaLevomilnacipran Hcl | 14 | $6,185 |
| Dyanavel XrAmphetamine | 13 | $5,536 |
| BelsomraSuvorexant | 13 | $5,418 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 13 | $2,810 |
| Lamotrigine ErLamotrigine | 21 | $1,381 |
| Clomipramine Hcl | 12 | $1,112 |
| Lithium Carbonate ErLithium Carbonate | 50 | $799 |
| Mirtazapine | 41 | $762 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 26 | $741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Fetzima | $1,282 | $84,78471 claims |
| Alkermes, Inc.Aristada | $2,137 | $33,97812 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $780 | $19,78731 claims |
| Axsome Therapeutics, Inc.Auvelity | $337 | $19,12322 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $86 | $7,68716 claims |
| Tris Pharma IncDyanavel Xr | $859 | $5,53613 claims |
| MerckBelsomra | $120 | $5,41813 claims |
| Almatica Pharma LLCSertraline Hcl | $475 | $10113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Riverside
- Evagelos CoskinasRiverside$7.3M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.